CrizotinibALK and KRAS mutations leading to acquired crizotinib resistance: 12 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2017年 / 1680卷 / 1期

关键词：

D O I：

10.1007/s40278-017-39030-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：99 / 99

相关论文

共 50 条

[1] CrizotinibALK mutations with acquired resistance to crizotinib: case report
Reactions Weekly, 2015, 1551 (1) : 89 - 89
[2] AntineoplasticsEGFR and KRAS mutations with acquired resistance to crizotinib: case report
Reactions Weekly, 2014, 1515 (1) : 31 - 31
[3] CrizotinibALK G1269A mutation leading to crizotinib resistance: case report
Reactions Weekly, 2017, 1680 (1) : 100 - 100
[4] KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA.
Del Re, Marzia
Bordi, Paola
Citi, Valentina
Crucitta, Stefania
Rofi, Eleonora
Petrini, Iacopo
Tiseo, Marcello
Danesi, Romano
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] Cetuximab/panitumumabEmergence of drug resistance due to KRAS mutations: 13 case reports
Reactions Weekly, 2016, 1586 (1) : 82 - 82
[6] Crizotinib/lorlatinibAcquired resistance: 11 case reports
Reactions Weekly, 2022, 1890 (1) : 93 - 93
[7] IbrutinibDevelopment of resistance mutations leading to disease progression: 2 case reports
Reactions Weekly, 2019, 1738 (1) : 144 - 144
[8] AlectinibALK I1171 (I1171N/S) mutations leading to acquired resistance: 2 case reports
Reactions Weekly, 2015, 1553 (1) : 25 - 25
[9] EntecavirDevelopment of resistance causing mutations leading to viral breakthrough: 13 case reports
Reactions Weekly, 2019, 1743 (1) : 84 - 84
[10] Crizotinib/lorlatinibAcquired drug resistance: 2 case reports
Reactions Weekly, 2022, 1922 (1) : 202 - 202

← 1 2 3 4 5 →